# Study Evaluation of Recombinant Hirudin in Prophylaxis of Post-Operative Deep Vein Thrombosis

> **NCT05847205** · PHASE4 · UNKNOWN · sponsor: **MinaPharm Pharmaceuticals** · enrollment: 100 (estimated)

## Conditions studied

- Prophylaxis of Deep Vein Thrombosis

## Interventions

- **DRUG:** r-Hirudin

## Key facts

- **NCT ID:** NCT05847205
- **Lead sponsor:** MinaPharm Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-24
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05847205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05847205, "Study Evaluation of Recombinant Hirudin in Prophylaxis of Post-Operative Deep Vein Thrombosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05847205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*